Downingtown, PA, United States of America

Lei Qiao

USPTO Granted Patents = 21 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.1

ph-index = 7

Forward Citations = 199(Granted Patents)

Location History:

Downington, PA (US) (2003)
Downingtown, PA (US) (2005 - 2024)
Dowingtown, PA (US) (2022 - 2024)

Company Filing History:

Incyte Holdings Corporation

Boehringer Ingelheim Pharmaceuticals, Inc.

Inctye Holdings Corporation

patent

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459943 - Crystalline solid forms of a BET inhibitor (2025-11-04),

2. 12427154 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2025-09-30),

3. 12043614 - Salts of a Pim kinase inhibitor (2024-07-23),

4. 12030882 - Crystalline solid forms of a bet inhibitor (2024-07-09),

5. 12024522 - Salts and processes of preparing a PI3K inhibitor (2024-07-02),

6. 11505540 - Salts of a Pim kinase inhibitor (2022-11-22),

7. 11452726 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2022-09-27),

8. 11377446 - Crystalline solid forms of a BET inhibitor (2022-07-05),

9. 11091480 - Crystalline solid forms of a BET inhibitor (2021-08-17),

10. 11084822 - Salts and processes of preparing a PI3K inhibitor (2021-08-10),

11. 10799509 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2020-10-13),

12. 10626114 - Crystalline solid forms of a BET inhibitor (2020-04-21),

13. 10336759 - Salts and processes of preparing a PI3K inhibitor (2019-07-02),

14. 10245265 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2019-04-02),

15. 10189832 - Crystalline solid forms of a BET inhibitor (2019-01-29),

Title: Lei Qiao: Innovator in Cancer Treatment

Introduction

Lei Qiao, based in Downingtown, PA, has made significant contributions to the field of biotechnology with a total of 19 patents to his name. His inventive work primarily focuses on developing innovative solutions for treating cancer, showcasing his dedication to improving patient outcomes through advanced therapeutic methods.

Latest Patents

Among his latest patents, one notable invention is centered around salts of a Pim kinase inhibitor. This invention relates to the salt forms of the compound N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide. It includes methods of preparation and intermediates, demonstrating significant utility in treating Pim kinase-related diseases, particularly cancer. Another of his recent patents involves crystalline solid forms of a BET protein inhibitor, which encompasses BRD2, BRD3, BRD4, and BRD-t. This patent also outlines methods of preparation and intermediates, aimed at addressing various cancer-associated diseases.

Career Highlights

Throughout his career, Lei Qiao has been associated with prominent organizations in the biopharmaceutical field, notably Incyte Corporation and Incyte Holdings Corporation. His work in these companies has enabled him to be at the forefront of research and development in therapeutic innovations, especially in oncology.

Collaborations

In his professional journey, Lei has collaborated with esteemed colleagues such as Jiacheng Zhou and Pingli Liu. These collaborations have played a pivotal role in advancing his research and expanding the impact of his inventions in the medical field.

Conclusion

With a strong portfolio of patents and a dedicated focus on cancer treatment, Lei Qiao exemplifies the spirit of innovation in biotechnology. His contributions not only enhance our understanding of cancer therapies but also pave the way for future advancements that could significantly benefit patients worldwide.

This text is generated by artificial intelligence and may not be accurate.